undefined undefined
NaN.000
NaN.00%
AI-discovered molecules can have an 80%–90% success rate in Phase 1 clinical studies, a group of researchers from Boston Consulting Group said in a recent peer-reviewed article in the journal Drug Dis...
05-11 02:13
The FDA has accepted Bristol-Myers (NYSE:BMY) biologics license application for a subcutaneous formulation of its oncology drug Opdivo, also known as nivolumab, with a target action date of Feb. 28. T...
05-07 00:11
Analyst Chris Shibutani from Goldman Sachs maintained a Hold rating on Schrodin...
05-03 21:55
启明创投成立于2006年,先后在中国上海、北京、苏州、香港及新加坡设立办公室。 启明创投投资企业中,很多已经成长为各自领域中最具影响力的公司,包括小米集团(...
05-03 08:16
Bristol-Myers Squibb (NYSE:BMY) has returned the rights to a preclinical cancer drug candidate, an SOS1 inhibitor, back to Schrodinger (NASDAQ:SDGR). Schrodinger noted that it delivered a development ...
05-03 03:04
Craig-Hallum:维持Schrodinger(SDGR.US)评级,由买入调整至买入评级, 目标价由35.00美元调整至30.00美元。
05-03 01:00
Unity Software(U.US) reported fourth-quarter financial results after the market...
05-03 00:59
2024 Software revenue growth is expected to range from 6% to 13%. Drug discovery revenue is expected to range from $30 million to $35 million. Software gross margin is
05-02 04:37
Schrodinger (NASDAQ:SDGR) reported quarterly Adj losses of $(0.86) per share which missed the analyst consensus estimate of $(0.75) by 14.67 percent. The company reported quarterly sales of $36.598 million which missed
05-02 04:06
启明创投成立于2006年,先后在中国上海、北京、苏州、香港及新加坡设立办公室。 启明创投投资企业中,很多已经成长为各自领域中最具影响力的公司,包括小米集团(...
05-01 08:16